Thanks to a solid rally this month, so far this year the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has managed to carve out a gain of approximately 4%.
While this is positive, it pales in comparison to some of the gains that have been witnessed on the market this year.
These two shares have gone gangbusters this year. Here's why:
The Big Un Ltd (ASX: BIG) share price has risen a staggering 878% this year. Investors have clearly been impressed with the video technology company's impressive rise in cash receipts. Thanks to heightened demand for its services Big Un reported a 429% increase in cash receipts to $21.5 million in FY 2017. This result beat its upgraded guidance by a wide margin. Pleasingly, thanks to sustained demand and its expansion overseas, Big Un's growth has continued in FY 2018. First-quarter cash receipts are expected to be approximately $15 million, up 488% on the prior corresponding period. While its shares are looking reasonably expensive now, I feel that if it can continue growing strongly it won't take long for the company to grow into its valuation.
The Wattle Health Australia Ltd (ASX: WHA) share price has gained over 700% since listing on the ASX at 20 cents per share in March. Investors have been fighting to get hold of Wattle Health shares largely because of its infant formula products. In November the company is expected to be granted CFDA approval to sell its infant formula in the China market from January 1 onwards when new regulations come into place. Rival a2 Milk Company Ltd (Australia) (ASX: A2M) is the only local company at present with approval thus far. If Wattle Health does get its approval it could potentially give it an advantage over its rivals. However, it is still a highly competitive market and having approval doesn't necessarily mean the product will sell. I'm keeping a close eye on Wattle Health and will be watching out for sales data early next year.
